Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Nivolumab

5

X.u Multiple organ dysfunction/failure (MODS/MOF)

1
Last update : 11/05/2018
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Avelumab
1
Durvalumab
3
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Lambrolizumab
4
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pembrolizumab
5

Publications

Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation.
Experimental hematology & oncology 2019;8;8 2019
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
The New England journal of medicine 2017 Jun 22;376;2415-2426 2017 Jun 22
Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review.
Journal of clinical neuromuscular disease 2017 Dec;19;80-83 2017 Dec

Powered by

  • ^
  • Contact
  • Cookies
  • About